1. Paenibacillus spp infection among infants with postinfectious hydrocephalus in Uganda: an observational case-control study.
- Author
-
Morton SU, Hehnly C, Burgoine K, Ssentongo P, Ericson JE, Kumar MS, Hagmann C, Fronterre C, Smith J, Movassagh M, Streck N, Bebell LM, Bazira J, Kumbakumba E, Bajunirwe F, Mulondo R, Mbabazi-Kabachelor E, Nsubuga BK, Natukwatsa D, Nalule E, Magombe J, Erickson T, Ngonzi J, Ochora M, Olupot-Olupot P, Onen J, Ssenyonga P, Mugamba J, Warf BC, Kulkarni AV, Lane J, Whalen AJ, Zhang L, Sheldon K, Meier FA, Kiwanuka J, Broach JR, Paulson JN, and Schiff SJ
- Subjects
- United States, Infant, Newborn, Child, Humans, Infant, Female, Pregnancy, Uganda epidemiology, Placenta, Case-Control Studies, Neonatal Sepsis complications, Paenibacillus genetics, Sepsis complications, Sepsis microbiology, Meningitis complications, Hydrocephalus epidemiology, Hydrocephalus etiology
- Abstract
Background: Paenibacillus thiaminolyticus is a cause of postinfectious hydrocephalus among Ugandan infants. To determine whether Paenibacillus spp is a pathogen in neonatal sepsis, meningitis, and postinfectious hydrocephalus, we aimed to complete three separate studies of Ugandan infants. The first study was on peripartum prevalence of Paenibacillus in mother-newborn pairs. The second study assessed Paenibacillus in blood and cerebrospinal fluid (CSF) from neonates with sepsis. The third study assessed Paenibacillus in CSF from infants with hydrocephalus., Methods: In this observational study, we recruited mother-newborn pairs with and without maternal fever (mother-newborn cohort), neonates (aged ≤28 days) with sepsis (sepsis cohort), and infants (aged ≤90 days) with hydrocephalus with and without a history of neonatal sepsis and meningitis (hydrocephalus cohort) from three hospitals in Uganda between Jan 13, 2016 and Oct 2, 2019. We collected maternal blood, vaginal swabs, and placental samples and the cord from the mother-newborn pairs, and blood and CSF from neonates and infants. Bacterial content of infant CSF was characterised by 16S rDNA sequencing. We analysed all samples using quantitative PCR (qPCR) targeting either the Paenibacillus genus or Paenibacillus thiaminolyticus spp. We collected cranial ultrasound and computed tomography images in the subset of participants represented in more than one cohort., Findings: No Paenibacillus spp were detected in vaginal, maternal blood, placental, or cord blood specimens from the mother-newborn cohort by qPCR. Paenibacillus spp was detected in 6% (37 of 631 neonates) in the sepsis cohort and, of these, 14% (5 of 37 neonates) developed postinfectious hydrocephalus. Paenibacillus was the most enriched bacterial genera in postinfectious hydrocephalus CSF (91 [44%] of 209 patients) from the hydrocephalus cohort, with 16S showing 94% accuracy when validated by qPCR. Imaging showed progression from Paenibacillus spp-related meningitis to postinfectious hydrocephalus over 1-3 months. Patients with postinfectious hydrocephalus with Paenibacillus spp infections were geographically clustered., Interpretation: Paenibacillus spp causes neonatal sepsis and meningitis in Uganda and is the dominant cause of subsequent postinfectious hydrocephalus. There was no evidence of transplacental transmission, and geographical evidence was consistent with an environmental source of neonatal infection. Further work is needed to identify routes of infection and optimise treatment of neonatal Paenibacillus spp infection to lessen the burden of morbidity and mortality., Funding: National Institutes of Health and Boston Children's Hospital Office of Faculty Development., Competing Interests: Declaration of interests KB is Principal Investigator on a Joint Global Health Trials grant from the UK Medical Research Council and has received travel grants and honoraria for speaking at Hot Topics in Neonatology. JEE has received honoraria for participation on the Data Safety Monitoring Board of AbbVie. BCW has received honoraria for participation on the Data Safety Monitoring Board for the Endoscopic versus Shunt Treatment of Hydrocephalus in Infants trial of the Hydrocephalus Clinical Research Network and is the Chairman of Neurokids. JNP has been employed by Genentech and N-Power Medicine; has held stocks and holds and is planning patents at Genentech and N-Power Medicine; has received honoraria for speaking at the International Human Microbiome Consortia meeting; and has received travel support from Genentech. All other authors declare no competing interests. The National Institutes of Health (NIH) Director's Pioneer Award 5DP1HD086071 and NIH Director's Transformative Award 1R01AI145057 has been given to SJS, and the Boston Children's Hospital Office of Faculty Development Career Development Award to SUM. No authors are employed by the NIH., (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF